Literature DB >> 19904234

Effect of genome size on AAV vector packaging.

Zhijian Wu1, Hongyan Yang, Peter Colosi.   

Abstract

Adeno-associated virus (AAV) vector genomes have been limited to 5 kilobases (kb) in length because their packaging limit was thought to be similar to the size of the parent AAV genome. Recent reports claim that significantly larger vector genomes can be packaged intact. We examined the packaged vector genomes from plasmid-encoded AAV vectors that ranged from 4.7 to 8.7 kb in length, using AAV types 2, 5, and 8 capsids. Southern blot analysis indicated that packaged AAV vector genomes never exceeded 5.2 kb in length irrespective of the size of the plasmid-encoded vector or the capsid type. This result was confirmed by vector genome probing with strand-specific oligonucleotides. The packaged vector genomes derived from plasmid-encoded vectors exceeding 5 kb were heterogeneous in length and truncated on the 5' end. Despite their truncated genomes, vector preparations produced from plasmid-encoded vectors exceeding 5.2 kb mediated reporter gene expression in vitro at high multiplicity of infection (MOI). The efficiency of expression was substantially lower than that of reporter vectors with genomes <5 kb in length. We propose that transcriptionally functional, intact vector genomes are generated in cells transduced at high MOI from the fragmentary genomes of these larger vectors, probably by recombination.

Entities:  

Mesh:

Year:  2009        PMID: 19904234      PMCID: PMC2839202          DOI: 10.1038/mt.2009.255

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  19 in total

1.  Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization.

Authors:  L Sun; J Li; X Xiao
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

5.  Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  Nat Biotechnol       Date:  2000-05       Impact factor: 54.908

6.  DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids.

Authors:  J A King; R Dubielzig; D Grimm; J A Kleinschmidt
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

7.  Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse.

Authors:  T K Park; Z Wu; S Kjellstrom; Y Zeng; R A Bush; P A Sieving; P Colosi
Journal:  Gene Ther       Date:  2009-05-21       Impact factor: 5.250

8.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

Review 9.  Leber congenital amaurosis: genes, proteins and disease mechanisms.

Authors:  Anneke I den Hollander; Ronald Roepman; Robert K Koenekoop; Frans P M Cremers
Journal:  Prog Retin Eye Res       Date:  2008-06-01       Impact factor: 21.198

10.  Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene.

Authors:  Christine L Halbert; James M Allen; A Dusty Miller
Journal:  Nat Biotechnol       Date:  2002-07       Impact factor: 54.908

View more
  312 in total

Review 1.  Gene therapy using stem cells.

Authors:  Erin R Burnight; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-13       Impact factor: 6.915

Review 2.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 3.  Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing.

Authors:  Manuel Kaulich; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2015-11-05       Impact factor: 5.486

Review 4.  Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery.

Authors:  Mehmet Fatih Bolukbasi; Ankit Gupta; Scot A Wolfe
Journal:  Nat Methods       Date:  2016-01       Impact factor: 28.547

Review 5.  Salient Features of Endonuclease Platforms for Therapeutic Genome Editing.

Authors:  Michael T Certo; Richard A Morgan
Journal:  Mol Ther       Date:  2016-01-22       Impact factor: 11.454

6.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

8.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

9.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

10.  PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage.

Authors:  Tautvydas Karvelis; Greta Bigelyte; Joshua K Young; Zhenglin Hou; Rimante Zedaveinyte; Karolina Budre; Sushmitha Paulraj; Vesna Djukanovic; Stephen Gasior; Arunas Silanskas; Česlovas Venclovas; Virginijus Siksnys
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.